Incyte Stock News

The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth potential in both the short term and the long run. Across varied sectors like healthcare, technology, and finance, as well as non-U.S. countries with growth potential, a select group of stocks can com...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST) Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT) The presentations will be webcast live and...

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI® (tafasitama...

Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS, PN, vitiligo, and asthma, with regulatory filings expected by early 2026. Oncology portfolio expansion is driven by INCA33890 for MSS colorectal cancer and INCB161734 for KRASG12D-mutated PDAC, bo...

Incyte Corporation (NASDAQ:INCY ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Alexis Smith William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Thomas Tray - Principal Financial Officer, VP of Finance & Chief Accounting Officer Steven Stein - Executive VP & Chief Medical Officer Mohamed Issa - Executive Vice President...

Incyte stock edged down Tuesday despite widely beating third-quarter forecasts, on its light 2025 outlook.

Drugmaker Incyte Corp on Tuesday raised its annual sales forecast for its blood cancer treatment Jakafi after robust demand for the drug helped the company surpass Wall Street estimates for third-quarter revenue and profit.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates.